Sarepta to Report Q2 Earnings: What's in Store for the Stock?

Sarepta Therapeutics (SRPT) is set to report Q2 2025 earnings on August 6, with preliminary net product revenues of $513 million, including $282 million from Elevidys, against a $530 million consensus estimate. The company has navigated significant operational challenges and safety concerns, including three patient deaths linked to its gene therapies which led to Elevidys' temporary market withdrawal; however, the FDA recently cleared its use for ambulatory patients, and Sarepta plans to resume shipments. Concurrently, SRPT initiated a major restructuring, cutting 36% of its workforce for $120 million in annual savings, and reprioritizing its pipeline from LGMD to new siRNA programs acquired from Arrowhead, with initial data for two programs anticipated by year-end. The company holds a Zacks Rank #4 (Sell) and has underperformed the industry year-to-date.

Analysis

Sarepta Therapeutics (SRPT) faces a pivotal second-quarter earnings report amid significant operational and safety challenges. The company's preliminary Q2 net product revenue of $513 million, including $282 million from its gene therapy Elevidys, tracks slightly below the consensus estimate of $530 million, setting a cautious tone. The core issue remains the safety profile of its AAVrh74 gene therapy vector, implicated in three patient deaths, which led to a temporary market withdrawal of Elevidys. While the FDA's recent clearance for ambulatory patients is a positive development, the path to resuming dosing in the non-ambulatory population remains uncertain and dependent on a new safety protocol. In response to these pressures, SRPT has initiated a substantial restructuring aimed at saving approximately $400 million annually by 2026. This plan involves a 36% workforce reduction and a strategic pipeline pivot, de-prioritizing its internal LGMD programs in favor of four newly licensed siRNA programs from Arrowhead Pharmaceuticals. This shift introduces new long-term growth drivers, with initial data for two programs expected by year-end, but also introduces integration and execution risk. The company's recent history of significant earnings misses, combined with a current Zacks Rank #4 (Sell), suggests considerable near-term headwinds and investor skepticism.

Key Decisions for Investors

• Investors should scrutinize the final Q2 earnings for any deviation from the preliminary figures and closely watch for updated sales guidance on Elevidys following its re-clearance for ambulatory patients, as this will be a key driver of near-term revenue.
• The primary risk factor is the ongoing safety concern for non-ambulatory patients; monitor for any updates on the new immunosuppression protocol and its submission to the FDA, as regaining access to this population is critical for Elevidys' long-term commercial success.
• Given the major restructuring and pipeline pivot to Arrowhead's siRNA platform, it is crucial to assess management's execution on cost-saving targets and upcoming clinical data catalysts before year-end, which represent the company's new long-term value proposition.
• Considering the stock's year-to-date underperformance, history of negative earnings surprises, and a 'Sell' rating from Zacks, a cautious stance is warranted until there is greater clarity on the commercial ramp-up of Elevidys and the tangible benefits of the restructuring.